332 related articles for article (PubMed ID: 30755483)
1. Methionine oxidation in α-synuclein inhibits its propensity for ordered secondary structure.
Ponzini E; De Palma A; Cerboni L; Natalello A; Rossi R; Moons R; Konijnenberg A; Narkiewicz J; Legname G; Sobott F; Mauri P; Santambrogio C; Grandori R
J Biol Chem; 2019 Apr; 294(14):5657-5665. PubMed ID: 30755483
[TBL] [Abstract][Full Text] [Related]
2. Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation.
Leong SL; Pham CL; Galatis D; Fodero-Tavoletti MT; Perez K; Hill AF; Masters CL; Ali FE; Barnham KJ; Cappai R
Free Radic Biol Med; 2009 May; 46(10):1328-37. PubMed ID: 19248830
[TBL] [Abstract][Full Text] [Related]
3. Role of individual methionines in the fibrillation of methionine-oxidized alpha-synuclein.
Hokenson MJ; Uversky VN; Goers J; Yamin G; Munishkina LA; Fink AL
Biochemistry; 2004 Apr; 43(15):4621-33. PubMed ID: 15078109
[TBL] [Abstract][Full Text] [Related]
4. How oxidized EGCG remodels α-synuclein fibrils into non-toxic aggregates: insights from computational simulations.
Gonçalves PB; Palhano FL; Cordeiro Y; Sodero ACR
Phys Chem Chem Phys; 2023 Jul; 25(28):19182-19194. PubMed ID: 37431676
[TBL] [Abstract][Full Text] [Related]
5. Dopamine-mediated oxidation of methionine 127 in α-synuclein causes cytotoxicity and oligomerization of α-synuclein.
Nakaso K; Tajima N; Ito S; Teraoka M; Yamashita A; Horikoshi Y; Kikuchi D; Mochida S; Nakashima K; Matsura T
PLoS One; 2013; 8(2):e55068. PubMed ID: 23457458
[TBL] [Abstract][Full Text] [Related]
6. The structure of dopamine induced alpha-synuclein oligomers.
Rekas A; Knott RB; Sokolova A; Barnham KJ; Perez KA; Masters CL; Drew SC; Cappai R; Curtain CC; Pham CL
Eur Biophys J; 2010 Sep; 39(10):1407-19. PubMed ID: 20309679
[TBL] [Abstract][Full Text] [Related]
7. Opposite Structural Effects of Epigallocatechin-3-gallate and Dopamine Binding to α-Synuclein.
Konijnenberg A; Ranica S; Narkiewicz J; Legname G; Grandori R; Sobott F; Natalello A
Anal Chem; 2016 Sep; 88(17):8468-75. PubMed ID: 27467405
[TBL] [Abstract][Full Text] [Related]
8. Methionine oxidation, alpha-synuclein and Parkinson's disease.
Glaser CB; Yamin G; Uversky VN; Fink AL
Biochim Biophys Acta; 2005 Jan; 1703(2):157-69. PubMed ID: 15680224
[TBL] [Abstract][Full Text] [Related]
9. The Aggregation Conditions Define Whether EGCG is an Inhibitor or Enhancer of
Sternke-Hoffmann R; Peduzzo A; Bolakhrif N; Haas R; Buell AK
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183378
[TBL] [Abstract][Full Text] [Related]
10. Binding of Noradrenaline to Native and Intermediate States during the Fibrillation of α-Synuclein Leads to the Formation of Stable and Structured Cytotoxic Species.
Singh P; Bhat R
ACS Chem Neurosci; 2019 Jun; 10(6):2741-2755. PubMed ID: 30917654
[TBL] [Abstract][Full Text] [Related]
11. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
[TBL] [Abstract][Full Text] [Related]
12. Cu
Ramis R; Ortega-Castro J; Vilanova B; Adrover M; Frau J
Int J Biol Macromol; 2021 Feb; 169():251-263. PubMed ID: 33345970
[TBL] [Abstract][Full Text] [Related]
13. Α-synuclein misfolding and Parkinson's disease.
Breydo L; Wu JW; Uversky VN
Biochim Biophys Acta; 2012 Feb; 1822(2):261-85. PubMed ID: 22024360
[TBL] [Abstract][Full Text] [Related]
14. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
15. Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro.
Uversky VN; Yamin G; Souillac PO; Goers J; Glaser CB; Fink AL
FEBS Lett; 2002 Apr; 517(1-3):239-44. PubMed ID: 12062445
[TBL] [Abstract][Full Text] [Related]
16. Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson's Disease.
Xu Y; Zhang Y; Quan Z; Wong W; Guo J; Zhang R; Yang Q; Dai R; McGeer PL; Qing H
Neurochem Res; 2016 Oct; 41(10):2788-2796. PubMed ID: 27364962
[TBL] [Abstract][Full Text] [Related]
17. EGCG has Dual and Opposing Effects on the N-terminal Region of Self-associating α-synuclein Oligomers.
Grønnemose AL; Østerlund EC; Otzen DE; Jørgensen TJD
J Mol Biol; 2022 Dec; 434(23):167855. PubMed ID: 36240861
[TBL] [Abstract][Full Text] [Related]
18. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner.
Pham CL; Leong SL; Ali FE; Kenche VB; Hill AF; Gras SL; Barnham KJ; Cappai R
J Mol Biol; 2009 Apr; 387(3):771-85. PubMed ID: 19361420
[TBL] [Abstract][Full Text] [Related]
19. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
Conway KA; Harper JD; Lansbury PT
Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
[TBL] [Abstract][Full Text] [Related]
20. Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation.
Qin Z; Hu D; Han S; Reaney SH; Di Monte DA; Fink AL
J Biol Chem; 2007 Feb; 282(8):5862-70. PubMed ID: 17189262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
